SLC13A5-IN-1 is a selective inhibitor of sodium-citrate co-transporter (SLC13A5/NaCT). It completely blocks the uptake of 14 C-citrate and has the potential for the treatment of metabolic and/or cardiovascular diseases.
[1] Joerg Kley, et al, WO2018104220A1
















